Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

121.46 -2.62 (-2.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,436,314
Open 124.24
Bid (Size) 120.87 (1)
Ask (Size) 121.89 (1)
Prev. Close 124.08
Today's Range 121.30 - 124.45
52wk Range 85.60 - 124.61
Shares Outstanding 1,253,809,440
Dividend Yield 2.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial
Via Stocktwits

Performance

YTD
+32.2%
+32.2%
1 Month
+8.0%
+8.0%
3 Month
+7.0%
+7.0%
6 Month
+14.2%
+14.2%
1 Year
+37.8%
+37.8%

More News

Read More
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
Via Stocktwits
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
Via Benzinga
Which S&P500 stocks are moving on Friday?
Via Chartmill
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
Via MarketMinute
Topics Retirement
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Via Benzinga
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
From Gilead Sciences, Inc.
Via Business Wire
Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
Via Get News
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
Via Benzinga
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'
Via Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
From Gilead Sciences, Inc.
Via Business Wire
3 S&P 500 Stocks We Approach with Caution
Via StockStory
Topics Intellectual Property Stocks
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
Breaking Down Gilead Sciences: 6 Analysts Share Their Views
Via Benzinga
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
Via Investor's Business Daily
Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investors
Via Chartmill
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Via Benzinga
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway
Via Stocktwits
Topics Intellectual Property
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Via Benzinga
Topics Intellectual Property
Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEO
Via Investor's Business Daily

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 121.46
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 10/22/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 152.29B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 152B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.